PTCT PTC Therapeutics, Inc.

NASDAQ
$66.06

PTC Therapeutics, Inc. (PTCT) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran below PTCT's own trailing one-year pace, with 91% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 7 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
9
67 transactions
Purchases
$0
0 shares
Sales
$25.2M
323,208 shares
Net activity
-$25.2M
purchases less sales

How much of that selling was preplanned? 91% planned / 9% discretionary

10b5-1 plan sales $23.0M 59 transactions · 293,171 shares
Discretionary sales $2.2M 8 transactions · 30,037 shares

Largest single sale: $2.7M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
SCHMERTZLER MICHAEL 2 fills Director Sell 10b5-1 12,500 $71.58 $894.8K 1,337,204 −0.9% of holding
SCHMERTZLER MICHAEL 2 fills Director Sell 10b5-1 12,500 $72.94 $911.7K 1,354,720 −0.9% of holding
SCHMERTZLER MICHAEL 3 fills Director Sell 10b5-1 12,500 $71.11 $888.9K 1,364,675 −0.9% of holding
SCHMERTZLER MICHAEL 2 fills Director Sell 10b5-1 12,500 $73.32 $916.6K 1,381,259 −0.9% of holding
Boulding Mark Elliott 2 fills EXEC. VP AND CLO Sell 10b5-1 2,813 $72.57 $204.1K 106,241 −2.6% of holding
Klein Matthew B. CHIEF EXECUTIVE OFFICER Sell 10,292 $68.57 $705.7K 383,868 −2.6% of holding
Gravier Pierre CHIEF FINANCIAL OFFICER Sell 3,494 $80.35 $280.7K 83,986 −4% of holding
Smith Mary L. 2 fills Director Sell 10b5-1 15,834 $90.00 $1.4M 21,813 −42.1% of holding
Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER Sell 10b5-1 2,464 $90.25 $222.4K 60,299 −3.9% of holding
Almstead Neil Gregory 3 fills CHIEF TECHNICAL OPS OFFICER Sell 10b5-1 24,613 $88.89 $2.2M 80,956 −23.3% of holding
Almstead Neil Gregory 5 fills CHIEF TECHNICAL OPS OFFICER Sell 10b5-1 22,161 $86.00 $1.9M 70,389 −23.9% of holding
Boulding Mark Elliott 8 fills EXEC. VP AND CLO Sell 10b5-1 5,079 $85.08 $432.1K 107,698 −4.5% of holding
Almstead Neil Gregory 2 fills CHIEF TECHNICAL OPS OFFICER Sell 10b5-1 8,130 $85.26 $693.2K 60,137 −11.9% of holding
Almstead Neil Gregory 5 fills CHIEF TECHNICAL OPS OFFICER Sell 10b5-1 20,960 $85.97 $1.8M 71,474 −22.7% of holding
Almstead Neil Gregory 2 fills CHIEF TECHNICAL OPS OFFICER Sell 10b5-1 5,323 $85.03 $452.6K 60,137 −8.1% of holding
Almstead Neil Gregory 2 fills CHIEF TECHNICAL OPS OFFICER Sell 10b5-1 23,749 $80.90 $1.9M 71,756 −24.9% of holding
Utter Christine Marie SVP, CHIEF ACCOUNTING OFFICER Sell 10b5-1 19,686 $75.56 $1.5M 70,199 −21.9% of holding
Boulding Mark Elliott 4 fills EXEC. VP AND CLO Sell 10b5-1 10,462 $78.65 $822.9K 107,122 −8.9% of holding
Pauwels Eric 2 fills CHIEF BUSINESS OFFICER Sell 10b5-1 21,277 $75.00 $1.6M 73,411 −22.5% of holding
Boulding Mark Elliott 2 fills EXEC. VP AND CLO Sell 10b5-1 2,812 $72.18 $203.0K 105,668 −2.6% of holding
Klein Matthew B. 4 fills CHIEF EXECUTIVE OFFICER Sell 12,572 $72.95 $917.2K 405,891 −3% of holding
Boulding Mark Elliott 4 fills EXEC. VP AND CLO Sell 10b5-1 3,540 $78.97 $279.6K 107,112 −3.2% of holding
Klein Matthew B. CHIEF EXECUTIVE OFFICER Sell 2,850 $70.91 $202.1K 394,070 −0.7% of holding
Boulding Mark Elliott 2 fills EXEC. VP AND CLO Sell 10b5-1 2,265 $69.45 $157.3K 106,655 −2.1% of holding
Golden Lee Scott EVP & CHIEF MEDICAL OFFICER Sell 829 $67.99 $56.4K 79,115 −1% of holding
Almstead Neil Gregory 3 fills CHIEF TECHNICAL OPS OFFICER Sell 10b5-1 52,003 $69.04 $3.6M 72,747 −41.7% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.